HIV drugmakers extend discounts for cash-strapped AIDS programs; Teva profits, sales drop on fewer generic launches;

h.i.v. infected t cell

@FiercePharma: Pharma tension rises in China as officials fine J&J, visit Sanofi; AZ chief anticipates pricing moves. News | Follow @FiercePharma

@CarlyHFierce:  Price controls in India triggering confusion for companies and consumers alike. Item | Follow @CarlyHFierce

> AbbVie ($ABBV), Gilead Sciences ($GILD), Merck ($MRK) and ViiV Healthcare agreed to extend discounts, rebates and pricing freezes for state AIDS Drug Assistance Programs through the end of next year, as funding sources for the programs run short. Report

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

> Teva Pharmaceutical Industries ($TEVA) saw profits drop 8.9% as the company launched fewer new generic medicines; sales fell by 1.4% to $4.92 billion. Report

> Mylan ($MYL) posted a 13% increase in earnings for the second quarter, on a 1% increase in sales to $1.7 billion. Release

> Doctors most often use their smartphones and tablets to access drug information, a new survey found. Report

Medical Device News

@FierceMedDev: Thoratec's revenue keeps rising, fueled by HeartMate sales. How long can the surge last? More | Follow @FierceMedDev

@MarkHFierce: Smith & Nephew can thank emerging markets, in part, for steady Q2 growth. More from Bloomberg | Follow @MarkHFierce

@DamianFierce: KKR is buying another CRO, planning to merge RPS with PRA once the transactions close. Report | Follow @DamianFierce

> Hansen eyes $93M, bigger share of robotic surgery market. News

> Covidien watches profits slide after kicking drugs. More

> How long can HeartMate pump Thoratec's revenue? Article

Biotech News

@FierceBiotech: PR: PharmAthene, Theraclone announce merger agreement to create #biologics co. targeting gov't and commerical markets. More | Follow @FierceBiotech

@JohnCFierce: Interesting to see Astra's Q2 report highlights late-stage deals. That took awhile. Makes a better case for near-term turnaround potential. | Follow @JohnCFierce

@RyanMFierce: Good time in biotech to find $: Karyopharm Therapeutics Secures $19 Million in Series B Financing Extension. Release | Follow @RyanMFierce

@EmilyMFierce: From FierceBiotechResearch.com: La Jolla, Kyowa Hakko Kirin partner on autoimmune disease drug discovery. Story | Follow @EmilyMFierce

> Analysis: AstraZeneca revs up new deals in shift to late-stage R&D turnaround. News

> Halozyme takes a second hit after safety fears scuttle PhII combo study. More

> Dicerna grabs $60M round to test RNAi tech on prime cancer suspect. Article

> Karyopharm snags $19M more to expand work on anticancer contender. Report

Pharma Manufacturing News

> Fresenius cans managers tied to data manipulation. Article

> CEO says Hospira is making progress on manufacturing fixes. Report

> India's price controls trigger labeling confusion. Item

> European gene-therapy pioneer to expand manufacturing with U.S. plant. News

Vaccines News

> Sanofi, MedImmune begin shipping flu vaccines. Item

> National action plans needed to stop hepatitis B, WHO says. Story

> GSK, Pfizer commit more vaccines to Unicef program. Article

> CDC: U.S. 'dropping the ball' on HPV vaccinations. More

And Finally... Exercise appears to change the way genes operate, offering a clue to how physical activity may help stave off diabetes and other diseases. Report

Suggested Articles

Amid a tough fight in the blood thinner market, J&J and Bayer's Xarelto scored a trial win in treating PAD patients after a recent leg artery surgery.

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.